How to Get Belsomra (Suvorexant) in Arizona

What Is Suvorexant and Why Does Access Matter in Arizona?

Suvorexant is a dual orexin receptor antagonist (DORA) that the FDA approved in 2014 for treating insomnia characterized by difficulty with sleep onset, sleep maintenance, or both [1]. Unlike benzodiazepines and Z-drugs, suvorexant works by blocking the wake-promoting orexin neuropeptides OX1R and OX2R rather than broadly depressing the central nervous system [2]. This mechanism produced a distinct safety profile in key trials. The phase III study by Herring et al. (Lancet Neurology, 2014) randomized 3,291 patients with insomnia to suvorexant (40 mg or 20 mg high-dose; 30 mg or 15 mg low-dose) or placebo over 12 months and found statistically significant improvements in both subjective total sleep time (sTST) and subjective time to sleep onset (sTSO) at month 1 and month 3 (P<0.001 for both endpoints) [1].

Arizona's population skews older in many counties, and chronic insomnia prevalence among adults aged 60 and older exceeds 30% nationally according to NIH data [3]. Access to a non-benzodiazepine sleep agent with lower abuse liability is clinically relevant in this demographic. Arizona also has expansive telehealth legislation, making remote prescribing of Schedule IV medications straightforward for patients in rural or underserved areas across the state.

Who Can Prescribe Belsomra in Arizona?

Any Arizona-licensed prescriber with an active DEA registration covering Schedule IV substances can prescribe suvorexant. That includes physicians (MD/DO), nurse practitioners, and physician assistants. Arizona removed the collaborative practice agreement requirement for NPs in 2001, so NPs with full practice authority can independently prescribe Belsomra without physician oversight [4].

PAs in Arizona prescribe under a supervisory agreement with a physician, but the agreement may authorize Schedule II through V controlled substance prescribing. The supervising physician does not need to co-sign each Belsomra prescription as long as the delegation agreement explicitly permits Schedule IV prescribing.

For patients in cities like Phoenix, Tucson, Scottsdale, or Flagstaff, finding a prescriber is rarely the bottleneck. The bottleneck is insurance coverage. Patients in rural counties (Apache, Greenlee, La Paz) may find telehealth the fastest path to a prescriber who is comfortable initiating a DORA.

Arizona Telehealth Prescribing Rules for Suvorexant

Arizona Revised Statutes §36-3602 define telehealth broadly and permit prescribing during an audio-video encounter without requiring a prior in-person visit [5]. Because suvorexant is Schedule IV, it falls within the scope of Arizona telehealth prescribing as long as the provider establishes a valid patient-provider relationship during the encounter.

A synchronous video visit is sufficient. The provider must document the clinical indication (insomnia disorder per DSM-5 or ICD-10 code G47.00), rule out contraindications, and transmit the prescription electronically to an Arizona-licensed pharmacy. Arizona does not require a separate in-person follow-up before the first refill, though most clinicians schedule a 4-to-6-week check-in to assess response and side effects.

The American Academy of Sleep Medicine (AASM) has endorsed telehealth for insomnia evaluation and management, noting that cognitive behavioral therapy for insomnia (CBT-I) delivered by telehealth shows non-inferior outcomes to in-person CBT-I [6]. Pairing a telehealth suvorexant prescription with telehealth CBT-I is an evidence-aligned approach that Arizona's regulatory framework supports.

What Labs or Assessments Are Needed Before Starting Belsomra?

Suvorexant does not require routine laboratory monitoring before initiation or during maintenance. The FDA-approved prescribing information does not mandate baseline bloodwork [2].

Prescribers should perform a clinical sleep assessment, which includes a structured sleep history (bedtime, wake time, latency, awakenings, daytime impairment), screening for obstructive sleep apnea (STOP-BANG questionnaire), and evaluation for narcolepsy or other hypersomnolence disorders. Suvorexant is contraindicated in patients with narcolepsy because blocking orexin signaling could worsen cataplexy [2].

A urine drug screen is not required by Arizona law for Schedule IV prescriptions but may be part of an individual practice's controlled substance policy. Liver function tests are reasonable in patients with known hepatic impairment since suvorexant is extensively metabolized by CYP3A4, and the FDA recommends dose reduction (maximum 10 mg) in moderate hepatic impairment and avoidance in severe hepatic impairment [2]. Most healthy adults will not need any labs before their first prescription.

Insurance Coverage and Prior Authorization in Arizona

Arizona Medicaid (AHCCCS) does not include Belsomra on its preferred drug list. Patients enrolled in AHCCCS plans will either need an exception request or will be directed to a preferred formulary alternative (typically generic zolpidem or trazodone).

Commercial insurers in Arizona (Blue Cross Blue Shield of Arizona, Cigna, Aetna, UnitedHealthcare) generally classify Belsomra as a non-preferred brand requiring prior authorization. The prior authorization process typically requires documentation of the following:

1. A diagnosis of insomnia disorder (ICD-10 G47.00 or G47.09)
2. Failure of, intolerance to, or contraindication for at least one preferred formulary agent (commonly generic zolpidem, eszopiclone, or trazodone)
3. A statement that the patient does not have narcolepsy
4. The prescriber's clinical rationale for selecting suvorexant over formulary alternatives

Turnaround on prior authorization decisions in Arizona ranges from 24 to 72 hours for standard requests. Arizona law requires insurers to respond to urgent prior authorization requests within 24 hours. If denied, patients have the right to an expedited appeal.

The Endocrine Society and AASM do not publish specific prior authorization guidelines for DORAs, but the AASM clinical practice guideline on pharmacotherapy for chronic insomnia (published in the Journal of Clinical Sleep Medicine) conditionally recommends suvorexant for sleep maintenance insomnia, which can support the clinical rationale section of a prior authorization letter [7].

Cost of Belsomra in Arizona Without Insurance

The average wholesale price (AWP) for a 30-tablet supply of Belsomra 10 mg or 20 mg exceeds $400. Retail cash prices at Arizona pharmacies vary:

• CVS and Walgreens locations in Phoenix and Tucson: approximately $430 to $480 for 30 tablets
• Costco pharmacies (Chandler, Gilbert, Surprise): approximately $390 to $420 for 30 tablets
• Independent pharmacies: prices vary widely, ranging from $350 to $500

Merck offers a Belsomra Savings Card for commercially insured patients, which may reduce the out-of-pocket cost to $0 for the first prescription and subsequent fills, subject to annual and per-fill limits. This card is not valid for patients with government insurance (Medicare Part D, AHCCCS, Tricare, VA).

For uninsured patients, Merck's patient assistance program (Merck Helps) provides Belsomra at no cost to qualifying individuals with household incomes below 400% of the federal poverty level. Application requires income documentation and prescriber certification.

503A Compounding Pharmacies and Suvorexant in Arizona

Arizona licenses 503A compounding pharmacies through the Arizona State Board of Pharmacy. These pharmacies can compound patient-specific prescriptions when a prescriber determines that a commercially available product does not meet a patient's medical need (for example, a patient who requires a dose not commercially available, or who cannot swallow tablets).

Suvorexant is commercially available in 5 mg, 10 mg, 15 mg, and 20 mg tablets. The clinical scenario for compounding is narrow. A prescriber might request a compounded suvorexant formulation for a patient who needs a liquid suspension due to dysphagia, though this is uncommon. 503A pharmacies in Arizona can ship compounded prescriptions within the state. Interstate shipping from a 503A pharmacy requires compliance with the resident state's board of pharmacy regulations and is generally limited to individual patient prescriptions, not bulk distribution.

Patients should verify that any 503A pharmacy they use holds an active Arizona Board of Pharmacy license and that the compounded product undergoes appropriate potency and sterility testing.

How Long Until You Receive Belsomra in Arizona?

Once a valid prescription reaches the pharmacy, standard dispensing takes 1 to 3 business days. Several factors influence the timeline:

No prior authorization needed (commercial insurance with Belsomra on formulary): Same-day or next-day fill is typical at chain pharmacies with suvorexant in stock. Not all locations stock Belsomra routinely because of its cost, so a 1-to-2-day order from the wholesaler may be required.

Prior authorization required: Add 1 to 3 business days for insurer review. If the PA is approved, the pharmacy can dispense immediately upon notification. If denied, an appeal adds 5 to 15 business days.

Cash pay or savings card: No PA delay. The pharmacy orders the medication if not in stock, typically arriving within 1 to 2 business days.

Mail-order pharmacy: Many Arizona commercial plans offer 90-day supplies through mail order (Express Scripts, CVS Caremark, OptumRx). Initial fill and shipping takes 5 to 10 business days. Subsequent refills can be set on auto-ship.

Transferring a Belsomra Prescription to an Arizona Pharmacy

Arizona follows DEA regulations for controlled substance prescription transfers. A Schedule IV prescription can be transferred between pharmacies, but the transfer must occur directly between the dispensing pharmacist at the originating pharmacy and the receiving pharmacist at the Arizona pharmacy, either by phone or through a shared electronic prescription network.

Each Schedule IV prescription may be transferred up to the number of authorized refills remaining. If the prescription originated in another state, the receiving Arizona pharmacist must verify the prescriber's DEA number and ensure the prescription complies with Arizona dispensing rules. The transfer must be documented in both pharmacies' records.

Patients relocating to Arizona from another state should contact their new Arizona pharmacy before their current supply runs out. The process is straightforward but cannot be completed by the patient alone. The pharmacists handle the transfer.

Suvorexant vs. Other Sleep Medications Available in Arizona

Arizona prescribers have access to the full range of FDA-approved insomnia pharmacotherapies. Understanding where suvorexant fits helps patients and providers make informed formulary decisions.

Generic zolpidem (Ambien) remains the most commonly prescribed sleep medication in Arizona, costs approximately $10 to $25 for a 30-day supply, and is covered by virtually all insurance plans including AHCCCS. The 2017 AASM guideline conditionally recommends zolpidem for sleep-onset insomnia [7]. Its primary limitations are short duration of action (the immediate-release form) and association with complex sleep behaviors.

Lemborexant (Dayvigo), another DORA approved in 2019, competes directly with suvorexant. The SUNRISE-2 trial (N=949) showed lemborexant 5 mg and 10 mg improved sTSO and sTST vs. placebo at 6 months [8]. Lemborexant is also a Schedule IV controlled substance with similar insurance hurdles in Arizona.

"The dual orexin receptor antagonists represent a meaningful advancement for patients with sleep maintenance insomnia who have not responded to or cannot tolerate GABA-modulating agents," according to the AASM 2017 clinical practice guideline [7]. This positions suvorexant as a second-line or alternative agent, not a first-line default, which is exactly how most Arizona formularies treat it.

The Herring et al. 2014 trial demonstrated that suvorexant at the approved 15 mg and 20 mg doses improved wake after sleep onset (WASO) by approximately 22 to 29 minutes vs. placebo at month 1 [1]. For a patient averaging 60+ minutes of nighttime wakefulness, a 25-minute reduction is clinically meaningful. For a patient with primarily sleep-onset difficulty, the benefit is more modest, and a short-acting agent might be preferred.

Safety Considerations Specific to Arizona Patients

Arizona's climate and lifestyle factors intersect with suvorexant's side effect profile in a few specific ways.

Daytime somnolence is the most common adverse effect, reported in 7% of patients taking suvorexant 15 mg or 20 mg vs. 3% on placebo in the Herring et al. trial [1]. Arizona's long driving distances, particularly in rural areas (Phoenix to Flagstaff: 145 miles; Tucson to Yuma: 240 miles), make next-morning drowsiness a practical safety concern. The FDA recommends that patients taking the 20 mg dose not drive or engage in activities requiring full alertness until they know how the drug affects them [2].

Suvorexant has no known interaction with heat exposure, UV exposure, or altitude. Patients in high-altitude Arizona communities (Flagstaff sits at 6,910 feet) do not need dose adjustments. Alcohol potentiates suvorexant's CNS-depressant effects. The FDA label advises against concurrent use [2].

Concomitant use of strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, certain HIV protease inhibitors) is contraindicated because these drugs substantially increase suvorexant plasma concentrations [2]. Moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, grapefruit juice) require a dose reduction to no more than 5 mg nightly. Arizona prescribers should review the patient's full medication list and dietary habits before initiating therapy.

Arizona's Prescription Drug Monitoring Program (PDMP) requires prescribers to check the PDMP before issuing a Schedule IV prescription. This check is completed electronically and takes less than a minute. It ensures the patient is not receiving overlapping controlled substance prescriptions from multiple providers, which reduces diversion risk and identifies patients who may benefit from coordinated care.